ZYDUSLIFE — Zydus Lifesciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Zydus Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	R2021 March 31st	C2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	144,035	151,099	172,374	195,474	232,415
Cost of Revenue
Gross Profit	89,608	88,614	101,811	125,064	160,103
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	118,730	125,231	149,888	150,259	174,818
Operating Profit	25,305	25,868	22,486	45,215	57,597
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	23,992	28,381	25,897	48,089	60,267
Provision for Income Taxes
Net Income After Taxes	22,056	23,264	20,019	38,314	46,148
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	21,336	44,873	19,603	38,595	45,255
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	21,336	44,873	19,603	38,595	45,255
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	23.4	21	23.8	37.9	46.4
Dividends per Share